InnoPharma, a subsidiary of Pfizer, focuses on advancing pharmaceutical technologies that enhance drug development and delivery. The company emphasizes the importance of precision medicine, which tailors treatments to individual patient needs, thereby improving therapeutic outcomes. Their commitment to innovation is evident in their exploration of gene therapy and mRNA technology, which represent cutting-edge approaches to treating various diseases. These technologies aim to harness the body's own mechanisms to combat illnesses, offering the potential for groundbreaking treatments that can significantly improve patient health.

Additionally, InnoPharma is dedicated to addressing complex health challenges through its work in areas such as oncology, inflammation and immunology, and rare diseases. The company employs a rigorous research and development process, involving extensive laboratory testing and clinical trials, to ensure the safety and efficacy of its products. By leveraging advanced biotechnological methods and maintaining a commitment to quality, InnoPharma strives to deliver innovative solutions that not only meet the needs of patients but also contribute to the overall advancement of healthcare.

United States

Generic and innovative specialty pharmaceutical products in injectable, ophthalmic dosage forms

InnoPharma (Pfizer)

Company Details